Your Health, We Care
In 2001, Stiripentol was recognized as an "orphan drug" by the European Union for its use in severe myoclonic epilepsy (SMEI) in infants.
In the international consensus on the diagnosis and treatment of Dravet syndrome (DS), Stiripentol is considered one of the second-line treatment drugs, reflecting its important position in the international field of antiepileptic drugs.
Dravet syndrome is a rare and refractory epileptic encephalopathy, and Stiripent···【more】
Release date：2024-08-28Recommended：158
Stiripentol is an innovative antiepileptic drug used to treat Dravet syndrome, m···【more】
Release date：2024-08-28Recommended：140
Stipentol is an anti-epileptic drug that reduces seizures primarily by boosting ···【more】
Release date：2024-08-27Recommended：120
